Answers are grounded in this paper and cite their sources.
Introduction Serum uric acid levels increase with progressive kidney disease, and chronic elevations may contribute to chronic kidney disease (CKD) progression. We analyzed data from the African American Study of Kidney Disease in Hypertension (AASK) to examine the hypothesis that individuals with declining serum urate levels during follow-up would experience slower loss of kidney function. Methods The AASK recruited 1094 African American individuals with reduced estimated glomerular filtration rate (eGFR) and followed them up to 12 years. The eGFR and defined end-stage kidney disease (ESKD) composite score were used to establish CKD stages. We employed a Cox proportional hazards model to investigate the association between uric acid trajectories and the composite ESKD outcome. Results Compared to the normal-increasing uric acid group ( i.e. , those who had the lowest overall serum uric acid levels), the high-stable (HR = 2.28, p = . 012), high-increasing (HR = 1.95, p = . 042), and extremely high-stable (HR = 3.21, p < 0.001) uric acid groups had higher risk of the composite ESKD outcome. The extremely high-stable group also had a greater ESKD risk than the high-decreasing group (HR = 1.98, p = .046). Adjustment for APOL1 risk allele, antihypertensive drug type, and mean arterial pressure treatment target did not alter the relationship between uric acid trajectories and the composite ESKD outcome. Conclusion Uric acid trajectories are associated with ESKD incidence in African Americans with CKD. Tracking temporal changs in uric acid improve the assessment of ESKD risk in CKD progression.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: